Cargando…
The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort
BACKGROUND: The current World Health Organization classification recognises 12 major subtypes of renal cell carcinoma (RCC). Although these subtypes differ on molecular and clinical levels, they are generally managed as the same disease, simply because they occur in the same organ. Specifically, the...
Autores principales: | Klatte, Tobias, Gallagher, Kevin M., Afferi, Luca, Volpe, Alessandro, Kroeger, Nils, Ribback, Silvia, McNeill, Alan, Riddick, Antony C. P., Armitage, James N., ‘Aho, Tevita F., Eisen, Tim, Fife, Kate, Bex, Axel, Pantuck, Allan J., Stewart, Grant D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775651/ https://www.ncbi.nlm.nih.gov/pubmed/31578141 http://dx.doi.org/10.1186/s12916-019-1419-1 |
Ejemplares similares
-
VENUSS rising for papillary renal cell carcinoma prognostication?
por: Buchler, Tomas
Publicado: (2020) -
Assessment of the VENUSS and GRANT Models for Individual Prediction of Cancer-specific Survival in Surgically Treated Nonmetastatic Papillary Renal Cell Carcinoma
por: Piccinelli, Mattia L., et al.
Publicado: (2023) -
Erratum to “Pomegranate Extracts in the Management of Men's Urologic Health: Scientific Rationale and Preclinical and Clinical Data”
por: Kroeger, Nils, et al.
Publicado: (2013) -
Thioredoxin 1 (Trx1) is associated with poor prognosis in clear cell renal cell carcinoma (ccRCC): an example for the crucial role of redox signaling in ccRCC
por: Ribback, Silvia, et al.
Publicado: (2021) -
Pomegranate Extracts in the Management of Men's Urologic Health: Scientific Rationale and Preclinical and Clinical Data
por: N., Kroeger, et al.
Publicado: (2013)